Two-year data from a phase 1/2 trial of eyeDNA Therapeutics' gene therapy for retinitis pigmentosa sets up pivotal trials, says the new biotech.

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Retinal dystrophies are a heterogeneous group of diseases in which the retina degenerates, leading to either partial or complete blindness. The severe and clearly hereditary forms, retinitis ...

Night blindness is caused by vitamin A deficiency, congenital mutations, and other eye diseases. Learn about symptoms, causes ...

The slackening of support from these companies coincides with the Trump administration's attacks on the LGBTQ community, ...

In addition, three specific mutations of the rhodopsin ( RHO) gene, which typically causes autosomal dominant-retinitis pigmentosa (see section on rod-cone dystrophies), have been associated with ...